Fig. 4.
Fig. 4. The addition of FL shifts the dose-response curve of EOL-1 cells treated with CEP-701. / (A) Graph displaying, as percent untreated control, proliferation (MTT; solid lines) and FLT3 phosphorylation (P-FLT3; dashed lines) in response to CEP-701 with (open circles) and without (solid circles) the presence of 100 ng/mL FL. Assays were performed as in Figure 3. (B) Immunoblot of phosphorylated FLT3 (P-FLT3; upper row) used for the graph in panel A. The same membrane stripped and reprobed with anti-FLT3 antibody is also shown (FLT3; lower row).

The addition of FL shifts the dose-response curve of EOL-1 cells treated with CEP-701.

(A) Graph displaying, as percent untreated control, proliferation (MTT; solid lines) and FLT3 phosphorylation (P-FLT3; dashed lines) in response to CEP-701 with (open circles) and without (solid circles) the presence of 100 ng/mL FL. Assays were performed as in Figure 3. (B) Immunoblot of phosphorylated FLT3 (P-FLT3; upper row) used for the graph in panel A. The same membrane stripped and reprobed with anti-FLT3 antibody is also shown (FLT3; lower row).

Close Modal

or Create an Account

Close Modal
Close Modal